Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464374 | 0.85 | CA12 (0.54) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL17420764 | 0.83 | SMN1; SMN2 (0.50) | CA12CA1CA2CA14SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL7313508 | 0.83 | CA12 (0.53) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL3306584 | 0.83 | SMN1; SMN2 (0.54) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL4340802 | 0.81 | AOC3 (0.53) | SMN1; SMN2KDM4EALDH1A1GAAPOLB | |
| SCHEMBL83159 | 0.80 | IDO1 (0.57) | CA12CA1CA2CA14KDM4E | |
| SCHEMBL3898720 | 0.79 | SMN1; SMN2 (0.50) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL216572 | 0.79 | SMN1; SMN2 (0.50) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL6270354 | 0.79 | ABCB1 (0.57) | CA12CA1CA2CA14SMN1; SMN2 | |
| SCHEMBL400747 | 0.79 | IDO1 (0.50) | CA12CA1CA2CA14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024111390-A1 | COMPOUND AND METHOD FOR PRODUCING SAME | 学校法人帝京大学 | 2024-05-30 | — | — | WO | claimed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | claimed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | claimed |
| US-6268310-B1 | CONTROLLING WEEDS | NIPPON SODA CO., LTD. (JP) | 2001-07-31 | — | — | US | claimed |
| US-4331597-A | AMOXYCILLIN DERIVATIVES | MEIJI SEIKA KAISHA, LTD. (JP) | 1982-05-25 | — | — | US | claimed |
| WO-2024111390-A1 | COMPOUND AND METHOD FOR PRODUCING SAME | 学校法人帝京大学 | 2024-05-30 | — | — | WO | disclosed |
| EP-2483287-B1 | ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS | PANZA LUIGI (IT) | 2016-03-16 | — | — | EP | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8697659-B2 | Analogues of glycolipids useful as immunoadjuvants | LUIGI PANZA (IT) | 2014-04-15 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-0359480-A1 | Mitomycin derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-03-21 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| US-4565874-A | Synthesis of parabactin and homologs thereof | UNIVERSITY OF FLORIDA (US) | 1986-01-21 | — | — | US | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4393058-A | BACTERICIDES | MEIJI SEIKA KAISHA, LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
| US-4331597-A | AMOXYCILLIN DERIVATIVES | MEIJI SEIKA KAISHA, LTD. (JP) | 1982-05-25 | — | — | US | disclosed |
| US-4183928-A | Haloarylmalonamidooxacephalosporins | SHIONOGI AND CO., LTD. (JP) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA12 4257/4885CA1 4506/4885CA2 3091/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | CA12 4653/4885CA1 3882/4885CA2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.